ArsenalBio, Hygieia Biosciences, and Shengshi Tech Secure New Funding Rounds to Advance Clinical Pipelines

Sep 09, 2024 21:10 CST Updated 21:10

ArsenalBio

Cell Therapy Developer

Hygieia

Small Interfering RNA (siRNA) Drug Developer

CGeneTech

Small Molecule Innovative Drug Developer

Over $300 Million Boost! Next-Generation CAR-T Therapy Has Entered Clinical Development

Arsenal Biosciences (ArsenalBio) recently announced the completion of a $325 million Series C financing round. The funds raised will be used to advance the development of ArsenalBio's core programs. The company will continue to build a research and development pipeline for cancer treatment based on its proprietary T-cell engineering technology. The funding will also be used to drive innovation and develop tools for discovering novel cell therapies.

ArsenalBio Aims to Reprogram T Cells Using CRISPR-Based Gene Editing, Enhancing Their Anti-Cancer Activity While Reducing Potential Toxicity. The company's CITE technology platform, based on CRISPR gene editing, precisely inserts the necessary components for genetic engineering into a specific location on chromosome 11 of T cells, thereby reducing the risk of mutations potentially caused by random insertions mediated by viral vectors.

Hygieia Pharmaceuticals Completes Tens of Millions of Yuan in Series A2 Financing, Accelerating Clinical Development of siRNA Pipeline

Recently, Hygieia Biopharmaceuticals (Hygieia) announced the completion of a multi-million RMB Series A2 financing round, led by Huangpu Biomedical Industry Fund with participation from Nanwan Biofund. Hygieia Biopharmaceuticals is committed to the construction of a technology platform for siRNA delivery and drug development, establishing an siRNA drug development platform with a pipeline covering hepatitis B, NASH/MASH, cardiovascular and metabolic diseases, complement-mediated diseases, and neurological disorders.

Hygieia Pharmaceuticals Co., Ltd. has licensed its siRNA drug for the treatment of chronic hepatitis B virus infection, developed by Fosun Pharma's subsidiary Starry Kunze, which has received approval from both the NMPA and FDA to enter clinical trials. The drug has demonstrated good safety, tolerability, and efficacy potential in Phase 1 clinical trials. The company also has two other pipelines in Phase 1 studies: Kylo-11 for the treatment of hyperlipoproteinemia (a), and Kylo-0603, a dual-target liver THRβ agonist pipeline.

CGeneTech Completes Over 100 Million Yuan in Series C Financing First Close

Recently, CGeneTech announced the first closing of its over 100-million-yuan Series C financing round, with the investment from Tongren Boda. The funds raised will be used for the commercialization of its Class 1 new drug product Sengliptin (formerly known as Shengliptin) and the clinical development of subsequent innovative pipelines. CGeneTech is committed to the R&D of differentiated small molecule innovative drugs and has established a rich pipeline covering hypoglycemic, anti-cancer, and autoimmune therapies, among which the DPP-4 inhibitor Sengliptin is about to be approved.

CGeneTech has multiple oncology pipelines entering the clinical stage. Among them, the new-generation small molecule CXCR4 antagonist CGT-1881 is under development for hematopoietic stem cell mobilization, the FGFR/VEGFR dual-target inhibitor CGT-6321 is being developed to treat solid tumors, and the next-generation ALK inhibitor CGT-9475 aims to address clinical challenges such as drug resistance and brain metastasis in lung cancer treatment. Notably, CGT-1881 and CGT-9475 have received FDA approval for clinical trials.

Editor: Mingyao